| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8922424 | Clinical and Translational Radiation Oncology | 2018 | 6 Pages |
Abstract
Long term outcomes and late toxicity were similar to previously reported series. The addition of gefitinib did not improve outcomes in LARC. Gefitinib is not recommended for rectal cancer patients who received 5-FU based preoperative CRT. Further studies may identify if gefitinib is beneficial in selected group of patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maria Antonietta Gambacorta, Antonino De Paoli, Marco Lupattelli, Giuditta Chiloiro, Angela Pia Solazzo, Brunella Barbaro, Sergio Alfieri, Fabio Maria Vecchio, Jacopo Lenkowicz, Francesco Navarria, Elisa Palazzari, Giulio Bertola, Alessandro Frattegiani,